Form 4: Eli Lilly Executive Melissa Seymour Acquires Restricted Stock Units

Melissa Seymour, an Executive Vice President at Eli Lilly, was granted 2,885 restricted stock units on August 1, 2024, which will vest over the next three years.

Summary

• Melissa Seymour, an Executive Vice President at Eli Lilly, received 2,885 restricted stock units on August 1, 2024.
• These restricted stock units represent a contingent right to receive one share of Eli Lilly common stock each.
• The units will vest in three installments: 952 on August 1, 2025, 981 on August 1, 2026, and 952 on August 1, 2027.
• The transaction was reported on August 2, 2024.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively for aligning management and shareholder interests. There are no negative implications.

Positives

• The grant of restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The restricted stock units will vest over the next three years, incentivizing the executive's long-term performance.

Industry Context

The granting of restricted stock units is a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Many pharmaceutical companies use restricted stock units as part of their executive compensation packages.
• Companies like Pfizer, Merck, and AbbVie also grant similar equity-based compensation to their executives.
• The vesting schedule of three years is also a common practice in the industry to ensure long-term alignment of interests.

Stakeholder Impact

• The grant of restricted stock units aligns the executive's interests with those of the shareholders, potentially leading to better long-term performance.
• The vesting schedule encourages long-term commitment from the executive, which can benefit the company and its stakeholders.

Key Dates

Keywords

restricted stock units, executive compensation, insider trading, stock options, equity, Eli Lilly, LLY